To evaluate role of the lymph node in immune regulation and tolerance in transplantation and recent advances in the delivery of antigen and immune modulatory signals to the lymph node.
INTRODUCTION
Transplantation has made incredible advances in past 60 years since the development of the first immunosuppressants. Immunosuppression used clinically today focuses on controlling the 'positive' immune response of activated T cells and donor-specific antibodies. These defensive strategies are not effective to induce tolerance, rely upon patients taking multiple medications daily, and have many side effects. Here, we shift our attention to the regulatory immune response and, specifically, the role of the lymph node.
Lymph nodes are the site of antigen presentation and activation of T and B lymphocytes. The development of cell-mediated, antibody-mediated, or regulatory immunity is modulated by different kinetics and combinations of immune signals. These signals alter the local microenvironment to promote cell interactions that translate into a systemic response [1, 2] . Thus, modulation of the lymph node microenvironment and its interaction with antigen has the potential to induce specific regulation and suppression and, eventually, tolerance.
LYMPH NODE STRUCTURE AND FUNCTION
Secondary lymphoid organs (SLO) form at predetermined locations and are highly dynamic structures.
A review of the path an antigen may take through the lymph node highlights potential targets that may be exploited for the future development of immune regulatory regimens (Table 1) .
Lymphatic vessels
Lymph drains from the interstitial space, enters lymphatic vessels, and is transported to lymph nodes [3, 48] . Chemokine ligand (CCL) 21 constitutively expressed on lymphatic vessels and CCR7 on T cells drives lymphocytes to the draining lymph node [5 & ,20,22] . Afferent lymph under homeostatic conditions is relatively low in cell density and comprised of mainly CD4 þ T cells with effector memory phenotype and dendritic cell, with a smaller proportion of monocytes, B cells, and granulocytes [5 & ]. Regulatory T-cell (Treg) migration from allografts to draining lymph nodes is mediated by CCR2, CCR5, and CXCR3 [39, 43] . Treg migration to the draining lymph node is a prerequisite for efficient suppression [21 & , 38, 39, 42, 43] . After reaching the afferent lymphatics of a draining lymph node, lymph travels around the periphery of the
KEY POINTS
Lymph nodes are a key nexus for integration of immune signals.
Lymph nodes can be accessed by blood, tissue, and direct routes for delivery of immune signals.
Lymph nodes can be specifically programed to generate suppressive and tolerogenic immune responses.
Recent advances in bioengineering techniques and materials demonstrate that lymph node programing is attainable. Lymph node zones Medulla Innermost layer, which is comprised of lymphocytes, plasma cell, macrophages, and the medullary cords and sinuses Point of entry from afferent lymph and exit via the efferent lymph S1P [13, 14] Paracortex (T-cell zone) Surrounds the medulla and is comprised of T cells, DC, and FRC Site of T-cell activation [13] Cortical ridge Marks boundary between paracortex and cortex, comprised of FRC and HEV Antigen presentation [13] Cortex (B-cell zone) Outermost layer of lymph node comprised of B cells, Bcell follicles, GC, macrophages, and FDC lymph node via the subcapsular sinus, through trabecular sinuses, and toward medullary sinuses, moving across lymphatic endothelial cells (LEC) into the lymph node parenchyma [5 & ,17,49] .
High endothelial venules
The second mode of entry into lymph nodes is from the blood across specialized cuboidal endothelial venous cells, the HEV. Migration into the parenchyma involves a multistep adhesion cascade [8] , mediated by the chemokine ligands CCL19 and CCL21 on HEV and their receptor, CCR7, on many leukocytes.
Reticular meshwork: a specialized stroma The HEV and lymphatic sinuses are connected to the lymph node parenchyma by stroma. The specialized stroma, summarized in Table 1 , is made of porous, reticulated fibers and extracellular matrix components that facilitate immune cell migration [19] . Two stromal cell types, LEC and fibroblastic reticular cell (FRC), are highlighted below.
Lymphatic endothelial cells
LECs line lymphatic vessels and secrete of sphingosine 1-phosphate (S1P) which binds to sphingosine 1 phosphate receptor 1 (S1PR1) on T cells. S1P-S1PR1 signaling regulates T-cell lymph node migration and maintains T-cell mitochondrial content, providing energy for constant migration and regulating the number of lymph node T cells [14,23 & ]. Under inflammatory conditions, LECs upregulate chemokine expression to fine-tune leukocyte recruitment to the lymphatic vessels [15,16,23 & ] (Table 1) . LECs use transcellular, in addition to paracellular pathways, to regulate solute transport into the lymph node in times of high flow, such as inflammation or injury [50] .
Fibroblastic reticular cells
FRCs line the lymphatic sinus and are specialized myofibroblasts. The FRC network acts as a scaffold that allows dendritic cell and T cells to traffic throughout the lymph node [27, 30] . FRC generate a CCL21 gradient that promotes T-cell retention via CCR7 [5 & ,36,51] . Podoplanin (or gp38) expression on FRC regulates contractility [28, 26] that alters the spacing of FRC and T cells within the lymph node.
Zones of the lymph node
The lymph node can be divided into four major zones: medulla, paracortex, cortical ridge, and cortex.
Medulla
Antigen-presenting macrophages reside with the subcapsular sinus [52] and regulate lymphocyte entrance into lymph node parenchyma via macrophage scavenger receptor -1 (MSR1) [6 & ] and antigen-specific cytotoxic T lymphocyte (CTL) responses via CD169 [34] . The innermost medulla is the point of entry from afferent for immune cells.
Resident dendritic cell migrate to the paracortex (T-cell zone) while migratory dendritic cell reside within the lymphatic sinus [53] [54] [55] . Dendritic cell positioning regulates interaction with antigens and the extent and quality of T-cell responses [56] .
Paracortex
The paracortex is known as the T-cell zone. Naïve CD4 þ T migration from the medulla toward the paracortex is CCR7 dependent [36] .
Cortical ridge
The cortical ridge is between the regions of the HEV, the paracortex, and the germinal centers of the cortex. Dendritic cell presents antigen to activate helper and cytotoxic T cells [31, 32] .
Cortex
The cortex contains T and B cell zones, and in particular the germinal centers, the sites of B-cell stimulation and maturation to antibody secreting cells [1, 44] .
Lymph node exit
Lymphocytes collect in the medulla of the lymph node and exit via the efferent lymphatics, which express endomucin, a ligand that prevents leukocyte adhesion [5 & ,6 & ,57]. T-cell egress from the lymph node is mediated by the low concentration of S1P within the lymph node and toward the higher levels within lymph, a process regulated by T-cell expression of S1PR1 and CD69 [45, 47] . T-cell retention in the lymph node is promoted by leukocyte-functionassociated antigen-1, common lymphatic endothelial and vascular endothelial receptor-1 (CLEVER-1), and macrophage mannose receptor with its ligand Lselectin [5 & ]. T-cell retention in the lymph node is also promoted by the drug FTY720 (fingolimod) [59] .
After resolution of an immune response and elimination of the antigen, lymph nodes resume a period of quiescence [58] , in which the structure and content are altered relative to the preimmune activation state [1] .
TARGETING APPROACH TO A LYMPH NODE AND CURRENT TECHNOLOGIES
The approaches to target lymph nodes mirror the entrance into a lymph node: interstitial tissue via afferent lymphatics, peripheral blood via the HEV, or direct entry via bioengineering techniques (Fig. 1) . It is worth noting that for all these approaches, addition of FTY720, may permit enhanced trafficking and retention of T cells within the lymph node [59] , and thus further augment exposure to immune regulatory bioengineering methods and materials.
Peripheral tissue to draining lymph node
Nanoparticles Small molecules enter lymphatic vessels either passively or after phagocytosis by APC, travel via interstitial flow into lymphatic capillaries, and drain into regional lymph nodes [60] . One technique for targeting lymph nodes uses nanoparticles. . Lymphocytes (pink), dendritic cell (blue), other cells (green), or artificial nanoparticles may enter the lymph node using either afferent lymphatic or arterioles, and exit from the lymph node is via the efferent lymphatic. Lymph enters the lymph node via the afferent lymphatic, moves around the periphery via the subcapsular sinus, down into the depth of the node via the trabecular sinuses, and enters the medullary sinuses at the innermost aspect of the lymph node. Entry into the parenchyma of the lymph node from the intravascular route is primarily at the medulla and via the high endothelial venules. The main zones of the lymph node are illustrated here from the innermost medullary cords, paracortex (T-cell zone), cortical ridge, and cortex (B-cell zone, in which germinal centers are generated.
Direct Injection Lymphatic

Intravascular
Nanoparticles are generally a collection of molecules between 1 and 100 nm, and can be solid, liquid, or gaseous [61] . Nanoparticles flow and lymphatic uptake is influenced by particle size, hydrophobicity, charge, and weight [62] . Nanoparticles measuring 25 nm efficiently and preferentially are taken up by lymph node resident macrophages and dendritic cell, compared with larger (100 nm) nanoparticles [60] . Most nanoparticles for medical applications are dispersed in a liquid and form micelles or emulsions. Micelles are a collection of amphiphilic surfactant molecules that aggregate in water and form a hydrophobic center, whereas nanoemulsions are two-phase mixtures consisting of a hydrophobic liquid core stabilized by a surfactant [61] . Nanoparticles can be delivered by many routes intramuscular, subcutaneous, hypodermic, microneedles [63] , intraperitoneal, or oral peritoneal. Microneedle patches may be used as a transcutaneous delivery system for nanoparticles in contrast to hypodermic needle [64 & ]. Oral administration is facilitated by self-emulsifying drug delivery systems, isotropic mixtures of drug, lipid, and surfactants that self-emulsify in the gastrointestinal tract and are passively absorbed into intestinal lymphatics [62] .
To promote lymphatic drug delivery, nanosized polymer-based carriers have been developed to encapsulate drugs. Polyethylene glycol modification nanoemulsions lower toxicity, increase halflife, and decrease immunogenicity by allowing the glycol units to form associations with water molecules and create a hydrophilic layer that prevents protein adsorption and clearance by macrophages. Micelles, which encapsulate hydrophobic drugs, can be injected intradermally, drained via lymphatics, and enter draining lymph node efficiently to exert immunosuppressive effects [65] .
Nanoparticles have been extensively studied in vaccine development. Immunization subcutaneously of mice with an antigen and nanoparticles containing Toll-like receptor (TLR) ligands (TLR4 and TLR7 ligands) enhanced antibody and T-cell responses compared with immunization with a soluble antigen [66] . Blocking this pathway in a transplant model may alter the microenvironment, dampen T-cell responses, and promote tolerance.
Typical limitations to peripheral tissue injection of nanoparticles, such as sequestration by the mononuclear phagocyte system and nonspecific distribution in SLO [67] , may play a less significant role when considering the use of nanoparticles to target lymph node. However, because lymphatic uptake and flow is a passive process and because nanoparticles may still undergo nonspecific cellular internalization [68] , nanoparticles pharmacokinetics remains a major limitation to this approach.
Another major limitation of nanoparticles is the lack of site-specific bioavailability. Thus, nanoparticles conjugated with ligands to target specific cells have been developed. Potential targets for lymph node and lymphatics include Lymphatic vessels endothelial hyaluron receptor 1, CLEVER-1, and MSR1 (Table 1) . Opsonization, as proteins bind to the nanoparticles surface, form a protein corona, defunctionalize surface ligands, and reduce the nanoparticles bioavailability [69, 70] . Liu et al. [71] developed a lipophilic oligonucleotide-albumin conjugate to exploit albumin 'hitch hiking', and produced a potent vaccine. An approach to antigen-specific tolerance in transplantation may be through use of these amphiphilic conjugates that efficiently accumulate in the lymph node.
Exosomes and macrophages M1 macrophages secrete proinflammatory cytokines to support the T H 1 immune response, whereas M2 macrophages support Th2 immunity, suppressing immune response and promoting wound healing [72 && ]. This is due, in part, to the secretion by these cells of exosomes. Exosomes are similar in physical property to nanoparticles and liposomes, which consist of an amphiphilic bilayer with an aqueous core, and could be considered a 'natural' nanoparticles.
Intralymph node macrophages and dendritic cell take up these exosomes, although the overall percentage of cells within a lymph node that take up exosomes is small (1%) [ [74] showed that exosomes carry both donor and recipient major histocompatibility complex (MHC) molecules, a phenomenon termed 'cross-dressing', to the lymph node and initiate allograft rejection. These findings are in contrast to the passenger leukocyte theory, which states that allograft rejection is initiated by recipient T cells recognizing donor leukocytes that traveled via lymphatics or blood to the regional lymph node [73 & ]. In a murine transplant model, they demonstrated a large number of 'crossdressed' recipient APCs (i.e., CD11c þ dendritic cell and CD20 þ B cells) within the draining lymph node and spleen following transplantation, compared with a small number of donor leu-
Nanoparticles coated with self-peptides bound to MHC class II molecules generate and expand an antigen-specific CD4
þ Treg type 1-like cells that abrogates autoimmunity [75] . This approach could be applied to transplant recipients with donor-specific antigens loaded on to MHC-class II-nanoparticles complexes.
Intraperitoneal route to lymph nodes
Intraperitoneal injection represents a special case of peripheral tissue injection because antigen, taken up by APC or soluble, may drain toward a lymph node or enter the vascular system. Furthermore, mesenteric lymph node and Peyer's Patches have unique features compared with peripheral lymph node, including innate lymphoid cells, from mucosa-associated tissue [76, 77] .
Shirali et al. demonstrated that after intraperitoneal injection, mycophenolic acid-coated nanoparticles were internalized by dendritic cell and macrophages that then trafficked to the spleen and lymph nodes. These nanoparticles delayed allograft rejection and at a log-fold lower dose than systemic mycophenolic acid [78] . Within lymph node and spleen, mice had significantly increased programmed death ligand-1 (PD-L1) expression by dendritic cell, suggesting this delivery technique leads to tolerogenic changes within the lymph node [78] . Similar results have been demonstrated with tacrolimus and cyclosporin A nanoparticles, which suppressed effector T cells and decreased T-cell proliferation [62, 79, 80] .
Peripheral blood to lymph node
Active lymph node targeting via high endothelial venules Naïve and memory T cells circulate between blood and lymph nodes, and lymphocyte trafficking to the lymph node is regulated by lymphocyte L-selectin [9, 10, 81] and HEV peripheral node addressins (PNAds). PNAd expression is increased in draining lymph nodes following transplantation [82 & ]. Azzi et al. developed an immunoregulatory microparticle to target the lymph node using an antibody that binds PNAd to deliver tacrolimus. This microparticle prolonged murine cardiac allograft survival [82 & ]. Increased survival was associated with a reduction of CD4 þ effector T cells in the lymph nodes [82 & ]. The trafficking of only 0.4-1.6% of the microparticle to the draining lymph node was low, probably related to its large size (2-5 mm) and the physical constraints of the FRC molecular sieve [29] . The results suggest that further development using PNAd or other HEV molecular markers (Table 1) will focus on engineering of microparticle physical characteristics.
Generation of antigen-specific regulatory T cell within the lymph node Because the tolerogenic effects in transplantation are often to be due to Tregs, another approach to altering the lymph node microenvironment centers on the generation of antigen-specific Tregs. This has been demonstrated in a chronic diabetic autoimmune murine model in which IV delivery of nanoparticles coated with disease relevant peptide and MHC promoted Treg development and suppressed antigen-specific presentation by APC within the lymph node [83] .
The aryl hydrocarbon receptor (AhR) pathway in dendritic cell, which can be induced with a mucosal ligand [ITE (1 0 H-indole-3 0 -carbonyl)-thiazole-4-carboxylic acid methyl ester)], controls the generation and differentiation of Tregs and Th17 cells [84, 85] . Yeste et al. [86] treated dendritic cell with nanoparticles that coadministered antigen with ITE ex vivo, thereby activating the AhR pathway, and induced a tolerogenic phenotype via expansion of FoxP3 Tregs in vivo. Although the intralymph node Tregs were not evaluated in this study, it is conceivable that this technique may influence the microenvironment of the lymph node after IV administration.
Manipulation of antigen presenting cell ex vivo
In response to infection or inflammation, dendritic cell mature, upregulate MHC and costimulatory molecules, and produce a variety of cytokines that promote the activation of naïve T cells and their differentiation into effector T cells, a mechanism that has been exploited (in vitro or in situ) for cancer and infectious vaccine development [87] [88] [89] . For tolerance development in transplantation, manipulation of APCs ex vivo has been performed using donor-specific transfusion (DST) or IV injection of antigen-coupled ethylene carbodiimide splenocytes (ECDI-SP) techniques.
Dendritic cell maturation is inhibited by Tregs via cytotoxic T lymphocyte antigen 4 and lymphocyte activation gene 3 coinhibitory ligands, transforming growth factor beta signaling, and IL-2 [90] . Leukemia inhibitory factor (LIF) is a member of the IL-6 family that promotes Treg development and immune tolerance [91] , and the use of LIF nanoparticles-bound APC with DST significantly, though modestly, prolonged allograft survival in a murine cardiac transplant model, which correlated with an expansion of antigen-specific FoxP3 þ cells within lymph node in murine and nonhuman primate invitro models [92] .
ECDI-SP can induce tolerance to autoantigen in transplant models by recipient CD11c þ dendritic cells that internalize donor ECDI-SP and selectively upregulate negative costimulatory molecules (PD-L1 and programmed death ligand -2) in the spleen and increase Tregs in draining lymph node [93] [94] [95] [96] . This approach was shown to be well tolerated and feasible in a phase 1 trial for multiple sclerosis patients [97] ; however, the complexity required using ex-vivo manipulation and high numbers of the cellular carriers for the ECDI-SP technique has since shifted focus toward biodegradable nanoparticles.
Direct lymph node manipulation
As the drainage and trafficking of antigen from peripheral tissue to a draining lymph node is variable and relatively inefficient [31, 32] , one mechanism that bypasses this process is the direct deposition of antigen via intralymph node (i.L.N.) injection [98, 99] . This method concentrates the antigen of interest at the site of T and B cell priming, which may drive more encounters of the injected antigen with the resident APC population and promote tolerance [100] . Tumor (foreign) cells directly injected into lymph node demonstrated swift rejection secondary to the generation of CTLs; however, tolerance was observed when tumors developed outside of the lymph node and tumor antigen was cross-presented to CD8 þ T cells in the draining lymph node [101] . The tolerogenic milieu is associated with plasmacytoid dendritic cell [102] and CD4 þ and CD8 þ Treg cell subtypes [103] . Given these encouraging results, a phase I clinical trial for i.L.N. allergen immunotherapy is on-going (ClinicalTrials.gov Identifier NCT01982474).
Our group has explored the generation of double emulsion microparticle that encapsulates rapamycin, a peptide fragment specific for the pathogenesis of multiple sclerosis, or the combination of both and the direct lymph node injection of these microparticle [98, 104] . Recently, we demonstrated in a murine model of multiple sclerosis that a single i.L.N. dose of microparticle with peptide fragment and rapamycin, given at the peak of disease, significantly reversed the multiple sclerosis disease severity as measured by clinical limb paralysis scores [105 && ]. Furthermore, these results were associated with the polarization of CD4 þ T cells toward a Treg phenotype within the cortical ridge of the lymph node and in noninjected tissue (i.e., spleen, pooled lymph nodes), decreased IL-17 and granulocyte macrophage colony stimulating factor production, and antigen-specific tolerance [105 && ]. The limitations of i.L.N. injection include the rapid clearance of antigen by flushing of afferent lymph [106] , technical challenges of lymph node mapping, and uncertainty of exact injection within the lymph node zones. Perhaps as microneedle development progresses, this technique could be utilized to yield a more consistent and evenly dispersed microparticle distribution within the node. This method also is dependent on the delivery of encapsulated, disease relevant self-antigen [105 && ], which in our current transplantation paradigm might only be applied to planned living donor transplantation.
CONCLUSION
Lymph nodes are the primary site of immune cell priming, activation, and modulation. Direct targeting of lymph nodes may be accomplished by considering the mechanisms of entry into the lymph node: from peripheral tissue via lymphatic vessels, from blood via HEV, or via direct injection. The use of nanoparticles, microparticle, and similar biotechnologies has allowed exploration and discovery of how manipulations of the lymph node microenvironment may affect systemic antigen-specific immune responses. Although the application of many of these techniques is still in its infancy for transplantation, the delivery of approved immunosuppressive medications via nanoparticles is feasible and may help to reduce the systemic burden of medications currently required by most transplant recipients. More novel techniques like harnessing M2 exosomes or exploring clinical application of i.L.N. injection may be further away from clinical trials; however, they hold significant potential for promoting tolerogenic microenvironments following transplantation.
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